Xeris Biopharma announces issuance of U.S. patent covering XeriSol formulations

Xeris Biopharma Holdings announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.’ The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris’ Gvoke product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations. "Xeris’ strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Paul R. Edick, Xeris’ Chairman and CEO. The Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris’ XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.